Artelo Biosciences files provisional patent for ART27.13 obesity use after mouse study shows up to 40% weight loss with semaglutide

• Artelo Biosciences filed a provisional patent application covering ART27.13 for obesity as a standalone treatment or with GLP-1 drugs.
• Results were already presented from a nonclinical obese-mouse study, with additional findings disclosed following data released on Sept. 16, 2026.
• ART27.13 showed meaningful weight-loss activity alone, with stronger results when combined with semaglutide.
• The combination also improved metabolic markers and showed a bone-health signal not seen in other study groups.
• The move positions ART27.13 as a potential add-on to GLP-1 therapies, supported by an existing clinical dataset across multiple studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230733PRIMZONEFULLFEED9832126) on September 23, 2026, and is solely responsible for the information contained therein.